First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance Therapy in Lung Adenocarcinoma Patients with Egfr Mutation (Convince)
Yuankai Shi,Lin Wang,Baohui Han,Wei Li,Ping Yu,Yunpeng Liu,Cuimin Ding,Xia Song,Ma Zhi Yong,Xinling Ren,Feng,Helong Zhang,Gongyan Chen,Ning Wu,Xiaohong Han,Chen Yao,Yong Song,Shucai Zhang,Lieming Ding,Fenlai Tan
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.9041
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:9041 Background: Icotinib is an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), which is non-inferior to gefitinib in treating unselected or EGFR-mutated advanced non-small cell lung cancer (NSCLC) patients as second-line therapy. We assess icotinib as first-line therapy in lung adenocarcinoma patients with EGFR mutation. Methods: This phase 3, open-label, randomized study (CONVINCE, NCT01719536) was conducted at 18 sites in China. Eligible patients (pathologically confirmed lung adenocarcinoma, 19/21 EGFR mutation, treatment naive) were 1:1 randomized to receive icotinib (125 mg, three times daily) or pemetrexed (500 mg/m2, day 1) plus cisplatine (75 mg/m2, day 1), non-progressive patients after 4-cycle chemotherapy continue to receive pemetrexed (500 mg/m2, day 1) as maintenance therapy until disease progression or intolerable toxicity. Randomization was stratified by performance status, smoking status, disease stage, and mutation type. The primary endpoint was progression free survival (PFS). Results: Six hundred and sixty-nine patients were screened (January, 2013 to August, 2014), in which 296 were enrolled and randomized (148 for each group), and 285 patients were treated (icotinib: 148, chemotherapy: 137). Baseline patients' characteristics were well balanced between groups. Icotinib significantly improved PFS (296 days [95% CI 255–355] vs 219 days [189–253]; HR 0.67, 95% CI 0.49-0.90, p = 0.008) compared with the chemotherapy group. Icotinib also showed better tumor response rate (64.8% vs 33.8%, p < 0.001). Significantly fewer adverse events (AEs) were seen in the icotinib group (104 [70.3%] vs 121 [88.3%], p < 0.001). The most common AEs were elevated transaminase (29.1%), rash (17.6%) and diarrhea (9.5%) in icotinib group,and were neutropenia (77.4%), erythropenia (76.6%), leukopenia (70.1%), nausea (54.7%), elevated transaminase (40.1%) in chemotherapy group. Conclusions: First-line icotinib is well tolerated and offers superior PFS compared with cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation. Clinical trial information: NCT01719536.